Wugen to Present Data on WU-NK-101 for Relapsed / Refractory Acute Myelogenous Leukemia at The American Society of Hematology’s (ASH) 64th Annual Meeting

SAINT LOUIS, MO and SAN DIEGO, CA, November 3, 2022 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of allogeneic cell therapies to treat a broad range of…

Read More

Wugen to Present at the Upcoming Jefferies Cell & Genetic Medicine Summit

SAINT LOUIS, MO and SAN DIEGO, CA, September 23, 2022 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of allogeneic cell therapies to treat a broad range of…

Read More

Wugen Presents Preclinical Data on WU-NK-101 in Solid Tumor Models at the European Society for Medical Oncology (ESMO) Congress 2022

-- WU-NK-101 exhibited enhanced metabolic fitness and adaptability, enabling superior resilience within the immunosuppressive solid tumor microenvironment and preserved cytotoxic function -- -- WU-NK-101 demonstrated robust anti-tumor activity, tumor trafficking, and…

Read More

Wugen Appoints Natalie Mount, Ph.D., as Chair of the Board of Directors

Cell therapy veteran Natalie Mount, Ph.D., brings more than 25 years of industry experience ST. LOUIS, MO and SAN DIEGO, CA, August 25, 2022- Wugen, Inc., a clinical-stage biotechnology company…

Read More

Wugen Receives U.S. FDA Fast Track and Rare Pediatric Disease Designations for WU-CART-007 for the Treatment of R/R T-ALL/LBL

ST. LOUIS, MO and SAN DIEGO, CA, July 19, 2022 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of allogeneic cell therapies to treat a broad range of hematological…

Read More

Wugen Presents New Preclinical Data Demonstrating Enhanced Anti-Tumor Activity of WU-NK-101 at the European Hematology Association (EHA) 2022 Hybrid Congress

-- WU-NK-101 exhibited enhanced metabolic flexibility and resistance to tumor microenvironment immunosuppression relative to conventional natural killer (NK) cells -- -- WU-NK-101 demonstrated robust anti-tumor activity in vitro and in…

Read More

Wugen to Participate in Upcoming June Investor Conferences

ST. LOUIS, MO and SAN DIEGO, CA, June 1, 2022- Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and…

Read More

Wugen to Present Preclinical Data on WU-NK-101 at the European Hematology Association (EHA) 2022 Hybrid Congress

ST. LOUIS, MO and SAN DIEGO, CA, May 12, 2022 –Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological…

Read More

Wugen to Participate in Upcoming April Investor Conferences

ST. LOUIS, MO and SAN DIEGO, CA, April 7, 2022 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of…

Read More

Wugen to Present at the Innate Killer Summit 2022

ST. LOUIS, MO and SAN DIEGO, CA, March 24, 2022 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of…

Read More